| **Annual Monitoring for Patients on Persistent Medications - Angiotensin Converting Enzyme (ACE) And Angiotensin Receptor Blockers (ARB)**  
| **Cardiology** |
| **Description** | The percentage of members 18 years and older who received at least a 180-day supply of ambulatory medication therapy for ACE and/or ARB during the measurement year and had at least one therapeutic monitoring event for the therapeutic agent in the measurement year. |
| **Performance Measurement Period** | January 1, 2012 through December 31, 2012 |
| **Methodology** | Administrative |
| **Ages Included** | 18 and older |
| **Products** | All Products |
| **Continuous Enrollment** | The measurement year |
| **Sample Size** | Full population |
| **Attribution** | The medical group of the prescribing provider's primary location of the most recent script that qualified the member for the denominator. Includes only scripts written by providers with the reported specialty. |
| **Frequency** | Annually |
| **Reported** | Provider eligibility is based on a minimum of 30 unique members for the measurement year. All provider groups are included in the overall rate calculation. |
| **Measures** | Annual Monitoring Rate |
| **Denominator** | Members 18 and older as of December 31st of the measurement year on persistent medications - defined as members who received at least a 180 days supply of ambulatory medication in the measurement year (NCQA's web site at www.ncqa.org provides a list of NDC codes for ACE/ARBS).  

To determine continuity of treatment during the 365 day period, sum the number of treatment days (days supply from all the scripts filled during the year) for a total of 180 days.  

NOTE: Members may switch therapy between ACE and ARB during the measurement year and have the days supply for those medications count toward the total 180 days supply (i.e. a member who received 90 days of ACE inhibitors and 90 days of ARB’s meets the denominator definition.) |
| **Numerator** | Number of members with at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year per HEDIS definitions.  

NOTE: The tests do not need to occur on the same service date, only within the measurement year. |
| **Rate Calculations** | Number of members with the required therapeutic monitoring test / Total number of members on persistent medications within each medical group. |
| **External Notes** |  

**Addendum Info** |

---

*HealthPartners Clinical Indicators*  
*Cardiology*
Annual Monitoring for Patients on Persistent Medications - Primary Care
Angiotensin Converting Enzyme (ACE) And Angiotensin Receptor Blockers (ARB)
1/1/2013 - 12/31/2013
# Annual Monitoring for Patients on Persistent Medications - Diuretics

**Primary Care**

## Description

The percentage of members 18 years and older who received at least a 180-day supply of ambulatory medication therapy for diuretics during the measurement year and had at least one therapeutic monitoring event for the therapeutic agent in the measurement year.

## Performance Measurement Period

January 1, 2012 through December 31, 2012

## Methodology

Administrative

## Ages Included

18 and older

## Products

All Products

## Continuous Enrollment

The measurement year

## Sample Size

Full population

## Attribution

The medical group of the prescribing provider's primary location of the most recent script that qualified the member for the denominator. Includes only scripts written by providers with the reported specialty.

## Frequency

Annually

## Reported

Provider eligibility is based on a minimum of 30 unique members for the measurement year. All provider groups are included in the overall rate calculation.

## Measures

Annual Monitoring Rate

### Denominator

Members on persistent medications – defined as members who received at least a 180 days supply of ambulatory medication in the measurement year (NCQA's web site at www.ncqa.org provides a list of NDC codes for Diuretics).

To determine continuity of treatment during the 365 day period, sum the number of treatment days (days supply from all the scripts filled during the year) for a total of 180 days.

### Numerator

Number of members with at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year per HEDIS definitions.

NOTE: The tests do not need to occur on the same service date, only within the measurement year.

### Rate Calculations

Number of members with the required therapeutic monitoring test / Total number of members on persistent medications within each medical group.

## External Notes

## Addendum Info

*HealthPartners Clinical Indicators*

*Primary Care*
Annual Monitoring for Patients on Persistent Medications - Primary Care
Diuretics
1/1/2013 - 12/31/2013

West Side Community Health Center
Burnsville Family Physicians, PA
Hutchinson Medical Center, PA
Multicare Associates of the Twin Cities
Southdale Internal Medicine
Western Wisconsin Medical Associates, SC Clinics
Amery Regional Medical Center Clinics
Entira Family Clinics
Sharpe, Dillon, Cockson, & Associates
HealthPartners Central Minnesota Clinics, Inc
HealthPartners Clinics
Fairview Clinics
HealthEast
Essentia Health - St. Joseph's Medical Center
North Memorial Health Care
Integrity - St. Cloud
Mayo Health System Clinics WI
Integrity - Buffalo
Allina Health
Park Nicollet Health Services
Essentia Health - SMDC Health System
Mayo Clinic
Hudson Hospital & Clinics
St. Croix Regional Medical Center
CentraCare Clinics
Ridgeview Clinics
Fairview Health Services Clinics
Stillwater Medical Group
United Family Medicine
Average Group
Unity Family Healthcare
Allina Health System Specialty Clinics
North Clinic, PA
Northwest Family Physicians, PA
Sanford Health - Fargo
Mayo Clinic Health System - Red Wing
Metropolitan Internists, PA
New Ulm Medical Center
Apple Valley Medical Clinic, Ltd
Hennepin County Medical Center
St. Luke's Clinics
Affiliated Community Medical Centers, PA
University of MN Physicians
Minnesota Rural Health Cooperative Clinics
Open Cities Health Center
Avera Health Clinics
Grand Itasca Clinic & Hospital
Mayo Health System Clinics MN
Olmsted Medical Center Clinics
Lakeview Clinic, Ltd
Atru Clinics
Mankato Clinic, Ltd

Percent with Monitoring
### Annual Monitoring for Patients on Persistent Medications - Angiotensin Converting Enzyme (ACE) And Angiotensin Receptor Blockers (ARB)

#### Cardiology

<table>
<thead>
<tr>
<th>Description</th>
<th>The percentage of members 18 years and older who received at least a 180-day supply of ambulatory medication therapy for ACE and/or ARB during the measurement year and had at least one therapeutic monitoring event for the therapeutic agent in the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Measurement Period</td>
<td>January 1, 2012 through December 31, 2012</td>
</tr>
<tr>
<td>Methodology</td>
<td>Administrative</td>
</tr>
<tr>
<td>Ages Included</td>
<td>18 and older</td>
</tr>
<tr>
<td>Products</td>
<td>All Products</td>
</tr>
<tr>
<td>Continuous Enrollment</td>
<td>The measurement year</td>
</tr>
<tr>
<td>Sample Size</td>
<td>Full population</td>
</tr>
<tr>
<td>Attribution</td>
<td>The medical group of the prescribing provider's primary location of the most recent script that qualified the member for the denominator. Includes only scripts written by providers with the reported specialty.</td>
</tr>
<tr>
<td>Frequency</td>
<td>Annually</td>
</tr>
<tr>
<td>Reported</td>
<td>Provider eligibility is based on a minimum of 30 unique members for the measurement year. All provider groups are included in the overall rate calculation.</td>
</tr>
<tr>
<td>Measures</td>
<td>Annual Monitoring Rate</td>
</tr>
<tr>
<td>Denominator</td>
<td>Members 18 and older as of December 31st of the measurement year on persistent medications - defined as members who received at least a 180 days supply of ambulatory medication in the measurement year (NCQA's web site at <a href="http://www.ncqa.org">www.ncqa.org</a> provides a list of NDC codes for ACE/ARBS). To determine continuity of treatment during the 365 day period, sum the number of treatment days (days supply from all the scripts filled during the year) for a total of 180 days. NOTE: Members may switch therapy between ACE and ARB during the measurement year and have the days supply for those medications count toward the total 180 days supply (i.e. a member who received 90 days of ACE inhibitors and 90 days of ARB's meets the denominator definition.)</td>
</tr>
<tr>
<td>Numerator</td>
<td>Number of members with at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year per HEDIS definitions. NOTE: The tests do not need to occur on the same service date, only within the measurement year.</td>
</tr>
<tr>
<td>Rate Calculations</td>
<td>Number of members with the required therapeutic monitoring test / Total number of members on persistent medications within each medical group.</td>
</tr>
</tbody>
</table>

### HealthPartners Clinical Indicators

**Cardiology**
Annual Monitoring for Patients on Persistent Medications - Cardiology
Angiotensin Converting Enzyme (ACE) And Angiotensin Receptor Blockers (ARB)
1/1/2013 - 12/31/2013
### Annual Monitoring for Patients on Persistent Medications - Diuretics

**Cardiology**

| **Description** | The percentage of members 18 years and older who received at least a 180-day supply of ambulatory medication therapy for diuretics during the measurement year and had at least one therapeutic monitoring event for the therapeutic agent in the measurement year. |
| **Performance Measurement Period** | January 1, 2012 through December 31, 2012 |
| **Methodology** | Administrative |
| **Ages Included** | 18 and older |
| **Products** | All Products |
| **Continuous Enrollment** | The measurement year |
| **Sample Size** | Full population |
| **Attribution** | The medical group of the prescribing provider’s primary location of the most recent script that qualified the member for the denominator. Includes only scripts written by providers with the reported specialty. |
| **Frequency** | Annually |
| **Reported** | Provider eligibility is based on a minimum of 30 unique members for the measurement year. All provider groups are included in the overall rate calculation. |
| **Measures** | Annual Monitoring Rate |
| **Denominator** | Members on persistent medications – defined as members who received at least a 180 days supply of ambulatory medication in the measurement year (NCQA's web site at www.ncqa.org provides a list of NDC codes for Diuretics). To determine continuity of treatment during the 365 day period, sum the number of treatment days (days supply from all the scripts filled during the year) for a total of 180 days. |
| **Numerator** | Number of members with at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year per HEDIS definitions. NOTE: The tests do not need to occur on the same service date, only within the measurement year. |
| **Rate Calculations** | Number of members with the required therapeutic monitoring test / Total number of members on persistent medications within each medical group. |

**HealthPartners Clinical Indicators**

**Cardiology**
Annual Monitoring for Patients on Persistent Medications - Cardiology
Diuretics
1/1/2013 - 12/31/2013

- Essentia Health - SMDC Health System
- HealthEast
- HealthPartners Clinics
- Metropolitan Heart & Vascular Institute
- Average Group
- Park Nicollet Health Services
- North Memorial Cardiovascular Services
- United Heart and Vascular Clinic
- University of Minnesota Physicians Heart at Fairview
- Minneapolis Heart Institute

Percent with Monitoring